Skip to main content

Advertisement

Fig. 2 | Respiratory Research

Fig. 2

From: The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics

Fig. 2

The role of the HVC model in the clinical development pathway. Short duration proof of concept studies, which incorporate the HVC model, typically include small numbers of subjects. The resulting safety and, particularly, efficacy data can more accurately guide decisions on whether to expose a larger number of subjects to promising candidate therapeutics in field studies than conventional phase 1 safety data alone otherwise might

Back to article page